Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) Equity Average: 2020-2025

Historic Equity Average for Apellis Pharmaceuticals (APLS) over the last 6 years, with Sep 2025 value amounting to $278.7 million.

  • Apellis Pharmaceuticals' Equity Average rose 11.17% to $278.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $278.7 million, marking a year-over-year increase of 11.17%. This contributed to the annual value of $211.5 million for FY2024, which is 16.10% up from last year.
  • As of Q3 2025, Apellis Pharmaceuticals' Equity Average stood at $278.7 million, which was up 73.93% from $160.3 million recorded in Q2 2025.
  • In the past 5 years, Apellis Pharmaceuticals' Equity Average ranged from a high of $378.8 million in Q2 2023 and a low of -$99.4 million during Q3 2021.
  • For the 3-year period, Apellis Pharmaceuticals' Equity Average averaged around $253.4 million, with its median value being $250.7 million (2024).
  • Per our database at Business Quant, Apellis Pharmaceuticals' Equity Average slumped by 158.84% in 2021 and then surged by 2,239.37% in 2023.
  • Over the past 5 years, Apellis Pharmaceuticals' Equity Average (Quarterly) stood at $70.7 million in 2021, then soared by 237.70% to $238.6 million in 2022, then decreased by 10.58% to $213.4 million in 2023, then grew by 9.11% to $232.8 million in 2024, then rose by 11.17% to $278.7 million in 2025.
  • Its Equity Average was $278.7 million in Q3 2025, compared to $160.3 million in Q2 2025 and $196.4 million in Q1 2025.